GRAIL, Inc.
GRAIL, Inc. (Nasdaq: GRAL) is a commercial-stage healthcare company developing blood-based tests for early cancer detection. Its main product, Galleri, analyzes DNA methylation patterns in blood to detect signals associated with more than 50 cancer types and predict the likely organ or tissue of origin; healthcare… From the company’s description.
Over the twelve months to Sep 30, 2026, GRAIL, Inc. reported revenue of $166.60M, up 17.5% from a year earlier, and a net loss of $406.18M. Its operating margin was −347.3%, and operations used $306.24M in cash. In fiscal 2025, it reported revenue of $147.17M, up 17.2% from fiscal 2024, and a net loss of $408.35M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What GRAIL, Inc. does
In the company’s own words
GRAIL, Inc. (Nasdaq: GRAL) is a commercial-stage healthcare company developing blood-based tests for early cancer detection. Its main product, Galleri, analyzes DNA methylation patterns in blood to detect signals associated with more than 50 cancer types and predict the likely organ or tissue of origin; healthcare providers use results to guide follow-up diagnostic testing. The company sells Galleri in the United States and works with healthcare systems, employers, digital health platforms, payors and life insurance providers, while also entering select international markets through distributors. Its targeted methylation platform also supports research-use-only and precision oncology applications, including biomarker discovery, recurrence detection and treatment monitoring, developed in collaboration with biopharmaceutical companies. GRAIL reports its business as one operating and reportable segment. Founded in 2016, it was spun off from Illumina in 2024. In 2025, it sold more than 185,000 commercial tests and reported revenue of $ million. Its website is https://grail.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- SUNNYVALE, CA
- Fiscal year end
- December
- CIK
- 1699031
- SIC
- 8071
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns GRAIL, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · GRAIL, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do GRAIL, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of GRAIL, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in GRAIL, Inc.'s last four quarterly filings that the numbers alone won't show?”